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Abstract 
Although the behavior of nanoscopic delivery systems in blood is an important parameter when 
contemplating their intravenous injection, this aspect is often poorly investigated when advancing 
from in vitro to in vivo experiments. In this paper, the behavior of siRNA loaded dextran nanogels in 
human plasma and blood is examined using fluorescence fluctuation spectroscopy, platelet 
aggregometry, flow cytometry and single particle tracking. Our results show that, in contrast to their 
negatively charged  counterparts, positively charged siRNA loaded dextran nanogels cause platelet 
aggregation and show increased binding to human blood cells. Although PEGylating the nanogels did 
not have a significant effect on their interaction with blood cells, single particle tracking revealed that 
it is necessary  to prevent their aggregation in human plasma. We therefore conclude that PEGylated 
negatively charged dextran nanogels are the most suited for further in vivo studies as they do not 
aggregate in human plasma and exhibit minimal interactions with blood cells. 
  
1. Introduction 
Although RNA interference (RNAi) is a promising strategy for treating various disorders [1-3], detailed 
knowledge and new scientific advancements are needed before this form of nucleic acid therapy can 
be applied clinically. Insufficient insights in endogenous gene regulation [4, 5] and especially 
difficulties regarding safe and efficient delivery of RNAi mediators are currently responsible for the 
inability of RNAi to live up to its full potential [6, 7]. Among these mediators, small interfering RNA 
(siRNA) is used the most for down regulation of mRNA in both clinical and research environments. 
Several routes of administration are currently investigated for siRNA [8] and although the advantages 
of local non invasive delivery are clear, many applications will require intravenous injection of 
(nanoscopic) siRNA carriers [9]. As this entails direct contact between these nanocarriers and blood 
components, profound knowledge on their behavior in blood is pivotal for the development of 
formulations which are not only efficient but also safe. Although of fundamental importance, safety 
is often only studied in a later stage of development. 
 Hemocompatible formulations can be defined as formulations which do not result in any form of 
toxicity and remain efficacious after being exposed to blood. Currently, complement activation, 
blood coagulation and hemolysis assays are the only tests regularly conducted when evaluating the 
hemocompatibility of new nanoformulations [10-13]. However, in addition to blood clotting, 
activation of the complement system and erythrocyte lysis, many other phenomena can occur. High 
salt and protein concentrations in blood, for instance, can destabilize nucleic acid loaded 
nanoparticles and seriously limit their efficacy, as illustrated recently by the disassembly of siRNA 
polyplexes upon contact with serum [14]. The latter can logically be explained by negatively charged 
serum components displacing the (negatively charged) siRNA, hereby exposing it to serum nucleases 
and fast glomerular filtration [15]. It is also common knowledge that nanosized particles in blood can 
be cleared efficiently by the mononuclear phagocyte system (MPS), thereby seriously limiting their 
blood circulation time and extravasation into target tissues [16-18]. Decreasing the susceptibility of 
nanocarriers to recognition by the MPS through coverage of their surface with hydrophilic polymers, 
such as polyethylene glycol (PEG), is an established strategy to prolong the residence time of a 
nanoformulation in the systemic circulation [16]. Aggregation of nanoparticles upon intravenous 
injection can also occur and is considered very important as it influences their clearance, bio-
distribution and toxicity [19-21]. Commonly used methods which study the size and aggregation of 
nanoparticles, e.g. dynamic light scattering (DLS), are however in most cases incompatible with 
complex media such as blood or serum. A recently developed technique based on fluorescence Single 
Particle Tracking (fSPT) allows size measurements of nanosized matter in undiluted human plasma 
[20] and is used in the current study to investigate the aggregation of nanoparticles, in this case 
dextran nanogels, in human plasma.  
 
 
Dextran nanogels have been proposed earlier as a nanocarrier system and have already been shown 
to successfully deliver siRNA in vitro [22, 23]. To further explore the potential of dextran nanogels for 
the intravenous delivery of siRNA, the first aim of this study is to evaluate to which extent siRNA 
loaded dextran nanogels are hemocompatible using several advanced methods that recently became 
available. Secondly, several new approaches which can provide additional information on the 
hemocompatibility of nanoformulations are introduced. In this regard we evaluate what 
aggregometry and flow cytometry can teach us about the interactions between nanogels and blood 
cells, under conditions closely resembling the in vivo situation. 
 
2. Materials and methods 
2.1 Preparation of PEGylated dextran nanogels loaded with siRNA 
Cationic dextran nanogels were prepared from dextran methacrylate (dex-MA), [2- 
(methacryloyloxy)ethyl]trimethylammonium chloride (TMAEMA) and 2-aminoethyl methacrylate 
hydrochloride (AEMA) using inverse mini-emulsion photopolymerization as described earlier [22, 23]. 
The resulting cationic nanogels of about 200 nm were lyophilized and stored in a desiccator at room 
temperature. A weighed amount of the lyophilizate was dispersed in a known volume of 20 mM 
HEPES buffer at pH 7.4 and exposed to a short burst of ultrasound to disintegrate loose particle 
aggregates formed during lyophilization (Branson Tip Sonifier, 10 s, amplitude 10%). The nanogels 
were loaded by adding increasing amounts of Dicer substrate 25/27-mer siRNA (DsiRNA) targeting 
EGFP (IDT, Leuven Belgium) to the initially positively charged nanogels. Increasing the siRNA/nanogel 
ratio resulted in neutral or negatively charged nanogels as described earlier [22, 23] (Figure 1). The 
nanogels were consecutively PEGylated by adding 0, 0.25, 0.5, 1, 2.5 and 5 mg NHS-PEG/mg nanogels 
N-hydroxysuccinimidyl activated methoxypolyethylene glycol 5000 propionic acid (NHS-PEG, Sigma, 
Belgium) for 30 min [23]. The influence of siRNA loading and PEGylation on the zeta potential of the 
nanogels is depicted in Figure S1 (supplementary information). 
 
2.2 Hemolysis assay 
The hemolytic activity of dextran nanogels was investigated using an established method based on 
the release of hemoglobin from damaged erythrocytes. Briefly, human erythrocytes were isolated 
from 5 mL of fresh citrated blood by centrifugation (600 g, 10 min). The erythrocytes were washed in 
PBS until the supernatant was clear and colorless and then diluted to the original volume of 5 mL. 50 
µL aliquots of the erythrocyte suspension were incubated with 50 µL of a nanogel dispersion for 30 
min at 37°C under constant shaking. For this experiment, both positively and negatively charged 
nanogels, with or without a PEG coating, were added in order to achieve final concentrations of 0.05 
to 0.5 mg nanogels/ml. After centrifugation (600 g, 10 min) to pellet the erythrocytes, the 
hemoglobin concentration in the supernatant was quantified using a UV-1800 UV-VIS 
Spectrophotometer (Shimadzu, Belgium) at 541 nm. A 1% triton X-100 solution and pure PBS were 
used as the positive and negative controls respectively and all samples were prepared in triplicate. 
 
2.3 Platelet aggregometry 
The use of blood or blood plasma inadvertently implies the presence of an anticoagulant to prevent 
rapid blood clotting. As high concentrations of negatively charged heparin can have a destabilizing 
effect on the siRNA loaded nanogels and EDTA is known to cause structural, biochemical and 
functional damage to platelets [24], trisodium citrate was used as an anticoagulant in accordance to 
clinical laboratory protocols.  
Fresh citrated blood was drawn from healthy volunteers and subsequently centrifuged at 280 g for 
15 min and 3200 g for 10 min to obtain platelet rich plasma (PRP) and platelet poor plasma (PPP) 
respectively. Using PPP, the platelet concentration of the PRP was adjusted to 3x106 cells per µL 
before pre-incubating 200 µL of this suspension at 37°C. 50 µL of a nanogel dispersion was added to 
the 200 µL of platelet dispersion to investigate nanogel induced platelet aggregation. The turbidity of 
the samples was measured as a function of time using a Chrono-log aggregometer (Kordia, Leiden, 
The Netherlands). 
 2.4 Fluorescence fluctuation spectroscopy 
The complexation degree of fluorescently labeled siRNA by dextran nanogels with different 
PEGylation degrees was determined in 20 mM HEPES buffer (pH 7.4) using fluorescence fluctuation 
spectroscopy (FFS) as reported before [23, 25]. FFS is a microscopy based technique that monitors 
the fluorescence intensity fluctuations in the focal volume (~1 fL) of a confocal microscope. When a 
solution of uncomplexed (i.e. free) fluorescently labeled siRNA is measured via FFS, a fluorescence 
signal proportional to the concentration of siRNA is obtained. Fluctuations in the fluorescence signal 
are caused by siRNA molecules diffusing in and out of the focal volume and result in a baseline signal. 
When the siRNA is complexed in nanoparticles, this baseline drops and highly fluorescent peaks 
(originating from nanoparticles containing large amounts of siRNA) occur. The shift of this baseline 
can be used to calculate the percentage of unbound siRNA as explained in detail by Buyens et al. 
[25]. 
 
To determine the extent of siRNA displacement from different nanogels by plasma constituents, FFS 
measurements were performed after incubating the siRNA loaded nanogels for 1h in human plasma 
(volume nanogels/plasma = 20/80). The final concentration of the nanogels was 0.068 mg/mL as this 
would be the theoretical concentration needed to deliver 1 mg/kg siRNA to a mouse. The 
experiments were conducted with both positively charged and negatively charged nanogels loaded 
with Alexa Fluor 488-labeled 25/27-mer siRNA (AF488-DsiRNA, IDT, Leuven, Belgium) targeting 
enhanced green fluorescent protein (EGFP). 
2.5 Fluorescence single particle tracking (fSPT) 
Single particle tracking (SPT) is a fluorescence microscopy-based method where the movement of 
individual fluorescently labeled particles or molecules is monitored in time and space. Using an epi-
fluorescence microscope adjusted for widefield laser illumination equipped with a fast and sensitive 
CCD camera, the movement of individual particles in biological fluids can be recorded under the form 
of movies. Particle trajectories subsequently calculated from these movies by specialized algorithms 
can then be used to measure both the size and number concentration of the particles, as recently 
shown by Braeckmans and colleagues [20]. 
 
2.5.1 Aggregation of nanogels in human plasma using fSPT 
Aggregation of negatively charged nanogels was followed as a function of time in both HEPES buffer 
and human plasma. Nanogel dispersions were prepared as described previously and were loaded 
with fluorescently labeled DsiRNA; the zeta potential of the non-PEGylated nanogels was 
approximately -10 mV. 5 µL of a nanogel dispersion was then incubated with 45 µL HEPES buffer or 
PPP at 37°C (0.068 mg nanogels/mL) and diluted 1:10 with buffer and PPP respectively immediately 
before the measurements. This particular concentration was selected as this would be the initial 
nanogel concentration in the blood of a mouse upon intravenous injection of a formulation 
containing 20 µg of siRNA. At each time point, 20 movies of 10 s each were recorded and 
consecutively analyzed to determine the size distribution of the nanogels. Using the nearest neighbor 
algorithm, trajectories were calculated taking into account the maximum distance a particle could 
reasonably have travelled in two consecutive frames. Using an algorithm based on the mean square 
displacement analysis, a mean diffusion coefficient could then be calculated for each trajectory. The 
distribution of these diffusion coefficients could be transformed in a size distribution using the 
Stokes-Einstein equation, provided that both the viscosity and the temperature of the sample were 
known. Both the objective and the sample were kept at 37°C during the measurement using an 
objective heater (Bioptechs, Butler, USA) and a sample heater (Linkam, Surrey, U.K.). During the 
calculations, the viscosity of human plasma was set to 1.35 cP at 37°C in accordance to Braeckmans 
et al [20]. Due to the stochastic nature of Brownian motion, the acquired size distribution was 
convoluted by a gamma distribution. Using a deconvolution algorithm known as the maximal entropy 
method (MEM), the actual size distribution was obtained [20]. 
 
2.5.2 Measuring the concentration of nanogels in human plasma using fSPT 
Although the number of calculated trajectories under 2.5.1 is not equal to the actual number of 
nanogels in a sample, a certain correlation exists between both values. Using additional information 
such as the detection volume, the track length and the diffusion coefficient of each particle, a 
maximum likelihood estimation could be used to determine the particle concentration in a 
dispersion. In this paper, this newly developed method is applied for the first time to estimate the 
number concentration of free nanogels in blood (i.e. non bound to cells). 
 
The experiments were performed as follows: PEGylated negatively charged nanogels were incubated 
with fresh citrated blood in different concentrations at 37°C for 1 hour prior to a short centrifugation 
step (600 g, 60 s) to remove the cell fraction. After the centrifugation step, 5 µL of the supernatant 
was placed on a heated microscopy slide for the collection of at least 20 movies of 10 seconds at 
approximately 22 fps. In order to calculate the fraction interacting with blood cells, the 
measurements were also performed in human plasma instead of full blood. Because the volume 
occupied by cells is not available for diffusing nanogels, the hematocrit value was used to correct the 
total volume of plasma. 
 
2.6 Flow cytometry 
Flow cytometry was used to investigate the adhesion and internalization of nanogels by blood cells. 
In order to compare various formulations, the fluorescence of every nanogel particle has to be 
similar. For this reason, a fixed amount of (green) fluorescently labeled siRNA (10 nmol per mg 
nanogels) was supplemented with unlabeled siRNA (0 to 20 nmol per mg nanogels) to achieve the 
desired siRNA loading and charge of the nanogels. The green fluorescence associated with a cell 
could be attributed to the sum of the adsorbed and internalized nanogels on/by this cell. By 
incubating the samples at 4°C instead of 37°C, active internalization of the nanogels by the cells can 
be inhibited and the green fluorescent signal associated with every cell can in this case be ascribed to 
labeled nanogels adsorbed on the surface. By treating the samples with trypan blue (Sigma Aldrich, 
Belgium) prior to the antibody labeling (see below), fluorescent nanogels attached to the surface of 
the cells are quenched so that only the internalized fraction of the nanogels is measured. Trypan blue 
quenching was performed by adding 25 µL of a trypan blue solution (0.2 %) to 5 µL of sample. After 5 
minutes incubation the trypan blue was subsequently removed by washing three times using PBS. 
The expertiments were performed as follows: 5 µL of a nanogel dispersion containing AF488-DsiRNA 
was incubated with 45 µl fresh citrated blood from healthy volunteers and incubated for 30 min at 
37°C. The final concentration of nanogels in blood was 0.068 mg nanogels/mL and all samples were 
prepared in triplicate. Antibodies against CD61 (platelets) and CD45 (leukocytes) conjugated to 
phycoerythrin (PE) and phycoerythrin-Cy5 (PE-Cy5) respectively were purchased from BD 
Pharmingen (Erembodegem, Belgium) and were used to resolve certain cell populations in blood. The 
scatter plot of the CD45 positive population was used to distinguish granulocytes, monocytes and 
lymphocytes. After 20 min at room temperature, unbound antibodies were washed away using PBS 
and a short centrifugation step (1100 g, 5 min). After discarding the supernatant, all samples were 
measured using a FACSCalibur flow cytometer (BD, Erembodegem, Belgium). The generated data was 
analyzed in SPSS using an ANOVA analysis (p < 0.05). 
 
3. Results and discussion 
3.1 Hemolysis 
With over 4 million cells per microliter, erythrocytes are abundantly present in human blood. As 
damage to erythrocytes and the subsequent release of hemoglobin causes the first symptoms of 
toxicity (e.g. renal failure), hemolysis assays are generally considered valuable in testing the 
hemocompatibility of a drug formulation. A standard hemolysis assay was performed to assess if 
siRNA loaded dextran nanogels induce erythrocyte lysis. Both positively and negatively charged 
nanogels, with different PEGylation degrees, were tested. As shown in Figure 2, the nanogels did not 
cause substantial erythrocyte lysis (< 1%), even not at high concentrations. The osmotic activity of 
nanocarrier dispersions is often neglected although it is known that especially erythrocytes are prone 
to osmotic disruption. Measurements using a freezing point depression osmometer indictated that 
the osmolarity of each nanogel dispersion (in PBS) studied in this paper was within the reference 
range of 275-299 mOsm per kg. A major disadvantage of a standard hemolysis assay is however the 
removal of the plasma components prior to the incubation of the erythrocytes with the nanoparticles 
as adsorption of plasma proteins on the nanoparticle surface can have an important influence on the 
interactions between cells and the nanoparticles [26]. 
 
3.2 Platelet aggregation 
Light transmission aggregometry is currently the standard method in clinical practice to evaluate 
platelet functions. By adding platelet activators to whole blood or platelet-rich plasma (PRP) and 
measuring the turbidity as a function of time, specific information can be obtained on possible 
platelet defects. Platelet clumping will result in a decreased turbidity of the sample due to the 
formation of a single clot. This method was used here to investigate whether nanogels induce 
undesired platelet clumping. Figure 3 shows that the addition of positively charged nanogels to PRP 
causes rapid aggregation of platelets while negatively charged nanogels do not (light transmission is 
~20% and similar to the transmission measured after adding buffer (negative control)). PEGylation of 
the nanogels did not influence the extent of platelet aggregation. While the hemolysis assay (Figure 
2) indicates all nanogel dispersions to be safe for erythrocytes, light transmission aggregometry 
suggests that positively charged nanogels cause extensive platelet aggregation (Figure 3). Based on 
these results, experiments in the continuation of this paper were generally conducted with 
negatively charged nanogels. 
 
3.3 Dissociation of siRNA loaded nanogels in human plasma 
Fluorescence fluctuation spectroscopy (FFS) was performed to measure the siRNA complexation 
efficiency by the nanogels upon contact with human plasma. As described before [25], FFS allows to 
distinguish between free and complexed siRNA in a sample without the need to physically separate 
the free and complexed molecules. Figure 4 shows that approximately 50% of the siRNA is released 
from the nanogels when dispersed in human plasma. PEGylation of the nanogels did not prevent this. 
All FFS experiments were performed at a nanogel concentration of 0.068 mg/ml which is the nanogel 
concentration in blood needed to deliver 1 mg/kg siRNA to a mouse (see 2.4). 
 
3.4 Aggregation of nanogels in human plasma 
Using fluorescent single particle tracking (fSPT), aggregation of nanogels in human plasma was 
studied. The results for negatively charged nanogels are depicted in Figure 5. In HEPES buffer, both 
non-PEGylated and PEGylated negatively charged nanogels were shown to be colloidally stable for at 
least 3 hours (Figure 5 A-D). In contrast, dispersing these nanogels in human plasma causes a marked 
aggregation of the non-PEGylated nanogels (Figure 5 E-H). Their aggregation could however be 
slowed down and even prevented by sufficiently coating the nanogels with PEG. Even for the highest 
PEGylation degree (5 mg NHSPEG/mg nanogel), a low number of aggregates were still detected. This 
is probably caused by a fraction of nanogels which is not sufficiently PEGylated (inhomogeneous 
PEGylation). Preventing nanoparticles from aggregating in blood is important as this will not only 
have an effect on their clearance and biodistribution but also on their toxicity, as illustrated by the 
accumulation of aggregated nanoparticles in lung capillaries upon intravenous injection. 
 
3.5 Adhesion and uptake of nanogels to/by blood cells 
Using flow cytometry, interactions between green fluorescent siRNA loaded nanogels and different 
cell populations in blood were examined. It was possible to measure the amount of nanogels 
internalized by the cells by quenching non internalized nanogels using trypan blue (Supplementary 
information, Figure S2). As shown in Figure 6A, all blood cell populations except erythrocytes show 
an outspoken charge dependent interaction with nanogels. Cationic nanogels clearly bind much more 
to cells than anionic ones. In contrast to surface charge, PEGylation of the nanogels did in most cases 
not influence the binding to the blood cells significantly (p < 0.05). 
 
As far as internalization of the nanogels by blood cells concerns (Figure 6B), monocytes and to a 
limited extent granulocytes, appeared to be the only cell types which efficiently internalize nanogels 
in a charge dependent manner. Although monocytes and neutrophilic granulocytes are both 
considered to be specialized phagocytes, the internalization of nanogels by neutrophils was low. 
These observations were confirmed by investigating the internalization of PEGylated, negatively 
charged nanogels as a function of time (Supplementary information, Figure S3.). In analogy to the 
binding, PEGylation of the nanogels did not influence their internalization by monocytes although it 
did prevent nanogel aggregation in human plasma (Figure 5). This could imply that the stabilizing 
effect of PEG is the primary reason for the longer blood circulation time associated with PEGylated 
formulations. 
 
Flow cytometry data in Figure 6 are in line with the outcome of the hemolysis (Figure 2) and 
aggregometry (Figure 3) assays. Figure 2 showed that nanogels do not cause erythrocytes lysis which 
can be expected as they do not bind to erythrocytes (Figure 6A). In addition, the binding of positively 
charged dextran nanogels to platelets (Figure 6B) support the results of the platelet aggregation 
assay in Figure 3. It seems that platelets do not internalize nanogels (Figure 6B) confirming that 
nanoparticles end up in the surface connected open canalicular system (OCS) of a platelet as 
suggested by Werb et al. [27]. 
 
As shown in Figure 7A, adding increasing amounts of nanogels to a fixed volume of blood revealed 
the saturation of the monocytes with nanogels at nanogel concentrations between 0.05 and 0.1 
mg/mL (which corresponds to ~6 billion and ~11 billion nanogels/mL respectively). It was however 
striking to see that the internalization of nanogels by monocytes decreased significantly at nanogel 
concentrations above 0.068 mg/mL (Figure 7B). A possible explanation is that phagocytosis is 
impaired above a critical nanoparticle concentration due to the large amount of nanogels adsorbed 
on the monocyte surface. This hypothesis is supported by the fact that the number of internalized 
nanogels (Figure 7B) decreases significantly at the concentration which corresponds to the saturation 
of the monocytes (Figure 7A). Interestingly, some early papers showed that monocytes can only 
engulf a finite quantity of particles or microorganism before entering a period of phagocytic inactivity 
[28, 29]. Visualization of the monocytes after incubation with the nanogels indeed revealed a high 
number of nanogels attached to the surface (Supplementary information, Video S1). To what extent 
saturation of the monocytes also influences their biological functions remains to be investigated. 
 
3.6 Interactions between nanogels and blood cells measured by fSPT 
To quantify the fraction of nanogels interacting with blood cells, the concentration of free (i.e. not 
adsorbed to cells) negatively charged PEGylated nanogels in blood was assessed by a method based 
on fSPT which calculates the concentration of fluorescent nanoparticles freely diffusing in a sample. 
As illustrated in Figure 8A, it is possible to calculate the percentage of nanogels bound to or 
internalized by blood cells by comparing the concentration of free nanogels measured in (platelet 
poor) plasma and blood. Figure 8B shows that increasing the number of nanogels added to a fixed 
volume of blood results in a larger fraction of free dextran nanogel suggesting that the blood cells are 
saturated with nanogels. At a nanogel concentration of 0.068 mg/mL (the concentration in blood 
needed to deliver 1 mg/kg siRNA to a mouse) approximately 69% of the nanogels remains free in 
blood while 31% is bound to/internalized by blood cells and is probably not able to extravasate into 
tissues. Flow cytometry data obtained under 3.5 (Figure 6A) were used to specify which of the 
different blood cell types are responsible for this 31% decrease in nanogel concentration (Figure 9). 
 
4. Conclusion 
In the context of developing a safe and efficient nanocarrier for drug delivery, the hemocompatibility 
of siRNA loaded dextran nanogels was investigated in this paper. Although none of the nanogel 
formulations caused significant erythrocyte lysis, positively charged nanogels induced platelet 
aggregation. Flow cytometry data confirmed that nanogels hardly bind to erythrocytes while a clear 
(charge dependent) interaction with platelets and leukocytes was observed. PEGylating the siRNA 
loaded dextran nanogels did not influence their interactions with cells significantly but was shown to 
be required to prevent their aggregation in human plasma. Based on these findings, PEGylated 
negatively charged siRNA loaded dextran nanogels are likely the safest formulation for in vivo siRNA 
delivery. However, the efficacy of this formulation will probably be influenced by the release of a 
significant fraction of the siRNA from the nanogels (approximately 50% in vitro) and their interactions 
with blood cells. 
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